Article(id=1329835595481854668, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329835512791150603, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2023.11.015, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1687104000000, receivedDateStr=2023-06-19, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794987113112, onlineDateStr=2026-11-18, pubDate=1699545600000, pubDateStr=2023-11-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794987113112, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794987113112, creator=13701087609, updateTime=1794987113112, updator=13701087609, issue=Issue{id=1329835512791150603, tenantId=1146029695717560320, journalId=1319690329412173987, year='2023', volume='44', issue='11', pageStart='1133', pageEnd='1242', issueExtLink='null', onlineDate='null', pubDate='1699545600000', pubDateStr='2023-11-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794987093398, creator='13701087609', updateTime=1794988063154, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329839580662051474, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329835512791150603, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329839580662051475, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329835512791150603, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1215, endPage=1218, ext={EN=ArticleExt(id=1329835597335737037, articleId=1329835595481854668, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research progress of sotagliflozin in cardiovascular disease, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Sotagliflozin is a drug with dual inhibitory effects on sodium-dependent glucose transporters (SGLT) 1 and 2. Inhibition of SGLT1 can inhibit glucose and galactose absorption in the digestive tract, and inhibition of SLGT2 can reduce glucose reabsorption in the renal tubules. Sotagliflozin has been shown to be effective in the treatment of type 2 diabetes mellitus. In recent years, it has shown great potential in cardiovascular diseases. Soglitazone can reduce adverse cardiovascular events in type 2 diabetes patients with cardiovascular risk factors. This article summarized the research on the application of sotagliflozin in diabetes mellitus complicated with cardiovascular diseases at home and abroad in recent years, in order to provide guidance for the further application of sotagliflozin in cardiovascular diseases.

, authors=Jianhua XU1, Shiya WANG2, *, authorsList=Jianhua XU, Shiya WANG, authorCompany=null, correspAuthors=Shiya WANG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329835597553840846, articleId=1329835595481854668, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=索格列净在心血管疾病中的研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

索格列净(sotagliflozin)是一种对钠-葡萄糖协同转运蛋白(sodium-dependent glucose transporters,SGLT)1、2有双重抑制作用的药物,对SGLT1的抑制可抑制消化道葡萄糖和半乳糖的吸收,对SLGT2抑制则是减少肾小管对葡萄糖的重吸收,已被证明可有效治疗2型糖尿病(diabetes mellitus)。近年来,其在心血管疾病方面显示出巨大潜力。索格列净能降低2型糖尿病伴心血管危险因素患者的心血管不良事件。该文通过对近年来国内外索格列净对糖尿病合并心血管疾病应用的研究进行归纳总结,以期为索格列净在心血管方面的进一步应用提供指导。

, authors=徐建华1, 王世亚2, *, authorsList=徐建华, 王世亚, authorCompany=null, correspAuthors=王世亚, authorNote=

徐建华,副主任药师,临床药学负责人,研究方向:心血管临床药学。

, correspAuthorsNote=
王世亚,副主任医师,心内科副主任,研究方向:心血管内科各种常见病的诊治。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=AX+xJvPKJI97YlS2QWGv7A==, magXml=dWJrf5go0TlM6xQ+3XyWdQ==, pdfUrl=null, pdf=IBTf+ub5pkkESYZ3RT18zA==, pdfFileSize=1516092, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=k2TbX9+QChDqMKv6CsbPYQ==, mapNumber=null, fund=null)}, authors=[Author(id=1329835598036185814, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329835598124266200, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, authorId=1329835598036185814, language=EN, stringName=Jianhua XU, firstName=Jianhua, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Clinical Pharmacy, Haian People's Hospital, Haian 226600, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835598191375065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, authorId=1329835598036185814, language=CN, stringName=徐建华, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.海安市人民医院临床药学室,江苏 海安 226600, bio={"content":"

徐建华,副主任药师,临床药学负责人,研究方向:心血管临床药学。

"}, bioImg=null, bioContent=

徐建华,副主任药师,临床药学负责人,研究方向:心血管临床药学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835597801304783, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, xref=1., ext=[AuthorCompanyExt(id=1329835597805499088, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, companyId=1329835597801304783, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Clinical Pharmacy, Haian People's Hospital, Haian 226600, Jiangsu Province, China), AuthorCompanyExt(id=1329835597818082001, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, companyId=1329835597801304783, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.海安市人民医院临床药学室,江苏 海安 226600)])]), Author(id=1329835598321398491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329835598422061789, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, authorId=1329835598321398491, language=EN, stringName=Shiya WANG, firstName=Shiya, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Cardiology, Haian People's Hospital, Haian 226600, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835598489170654, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, authorId=1329835598321398491, language=CN, stringName=王世亚, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.海安市人民医院心血管内科,江苏 海安 226600, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835597889385170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, xref=2., ext=[AuthorCompanyExt(id=1329835597901968083, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, companyId=1329835597889385170, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Cardiology, Haian People's Hospital, Haian 226600, Jiangsu Province, China), AuthorCompanyExt(id=1329835597914550996, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, companyId=1329835597889385170, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.海安市人民医院心血管内科,江苏 海安 226600)])])], keywords=[Keyword(id=1329835598598222559, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, language=EN, orderNo=1, keyword=sotagliflozin), Keyword(id=1329835598669525728, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, language=EN, orderNo=2, keyword=diabetes melltius), Keyword(id=1329835598740828897, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, language=EN, orderNo=3, keyword=cardiovascular), Keyword(id=1329835598816326370, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, language=EN, orderNo=4, keyword=heart failure), Keyword(id=1329835598891823843, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, language=CN, orderNo=1, keyword=索格列净), Keyword(id=1329835598984098532, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, language=CN, orderNo=2, keyword=糖尿病), Keyword(id=1329835599042818789, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, language=CN, orderNo=3, keyword=心血管), Keyword(id=1329835599126704870, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, language=CN, orderNo=4, keyword=心力衰竭)], refs=[Reference(id=1329835599323837160, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=李钰. 新型降糖药对2型糖尿病患者卒中和心血管结局影响的meta分析[D]. 石家庄: 河北医科大学, 2022., articleTitle=null, refAbstract=null), Reference(id=1329835599390946025, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Scirica BM, Bhatt DL, Braunwald E, et al. Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial[J]. J Am Med Assoc Cardiol, 2016, 1(9): 989-998., articleTitle=null, refAbstract=null), Reference(id=1329835599449666282, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=潘丽. 糖尿病与心血管疾病相互联系分析[J]. 糖尿病新世界, 2015, (7): 134., articleTitle=null, refAbstract=null), Reference(id=1329835599516775147, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=朱思梅, 杨汉跃, 王建涛. SGLT1/SGLT2双重抑制剂索格列净用于1型糖尿病的研究进展[J]. 中国新药与临床杂志, 2018, 37(10): 537-540., articleTitle=null, refAbstract=null), Reference(id=1329835599575495404, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=杨中兴, 贺岩, 杨龙, 等. SGLT1/2双靶点抑制剂的研究进展[J]. 中南药学, 2021, 19(9): 1776-1785., articleTitle=null, refAbstract=null), Reference(id=1329835599642604269, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Powell DR, Zambrowicz B, Morrow L, et al. Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption[J]. J Clin Endocrinol Metab, 2020, 105(4): e1235-e1249., articleTitle=null, refAbstract=null), Reference(id=1329835599718101742, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Seidelmann SB, Feofanova E, Yu B, et al. Genetic variants in SGLT1, glucose tolerance, and cardiometabolic risk[J]. J Am Coll Cardiol, 2018, 72(15): 1763-1773., articleTitle=null, refAbstract=null), Reference(id=1329835599789404911, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure[J]. N Engl J Med, 2021, 384(2): 117-128., articleTitle=null, refAbstract=null), Reference(id=1329835599877485296, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4): 347-357., articleTitle=null, refAbstract=null), Reference(id=1329835599940399857, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus[J]. Circulation, 2019, 139(22): 2528-2536., articleTitle=null, refAbstract=null), Reference(id=1329835601555206898, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med, 2020, 383(15): 1436-1446., articleTitle=null, refAbstract=null), Reference(id=1329835601655870195, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes[J]. N Engl J Med, 2020, 383(15): 1425-1435., articleTitle=null, refAbstract=null), Reference(id=1329835601731367668, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)[J]. Eur J Heart Fail, 2020, 22(4): 713-722., articleTitle=null, refAbstract=null), Reference(id=1329835601819448053, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Verma S, Mazer CD, Bhatt DL, et al. Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG outcome trial[J]. Diabetes Care, 2019, 42(3): e42-e44., articleTitle=null, refAbstract=null), Reference(id=1329835601894945526, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Verma S, Mazer CD, Yan AT, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial[J]. Circulation, 2019, 140(21): 1693-1702., articleTitle=null, refAbstract=null), Reference(id=1329835601970442999, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Opingari E, Verma S, Connelly KA, et al. The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of empagliflozin on cardiac structure, function, and circulating biomarkers in patients with type 2 diabetes CardioLink-6 trial[J]. Nephrol Dial Transplant, 2020, 35(5): 895-897., articleTitle=null, refAbstract=null), Reference(id=1329835602033357560, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease[J]. N Engl J Med, 2021, 384(2): 129-139., articleTitle=null, refAbstract=null), Reference(id=1329835602104660729, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Bagiella E, Bhatt DL, Gaudino M. The consequences of the COVID-19 pandemic on non-COVID-19 clinical trials[J]. J Am Coll Cardiol, 2020, 76(3): 342-345., articleTitle=null, refAbstract=null), Reference(id=1329835602192741114, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Gaba P, Bhatt DL. The COVID-19 pandemic: a catalyst to improve clinical trials[J]. Nat Rev Cardiol, 2020, 17(11): 673-675., articleTitle=null, refAbstract=null), Reference(id=1329835602259849979, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Gaudino M, Arvind V, Hameed I, et al. Effects of the COVID pandemic on active non-COVID clinical trials[J]. J Am Coll Cardiol, 2020, 76(13): 1605-1606., articleTitle=null, refAbstract=null), Reference(id=1329835602339541756, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Selvaraj S, Greene SJ, Khatana SAM, et al. The landscape of cardiovascular clinical trials in the United States initiated before and during COVID-19[J]. J Am Heart Assoc, 2020, 9(18): e018274., articleTitle=null, refAbstract=null), Reference(id=1329835602419233533, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22): 2117-2128., articleTitle=null, refAbstract=null), Reference(id=1329835602486342398, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Neal B, PerkovicV, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med, 2017, 377(21): 2099., articleTitle=null, refAbstract=null), Reference(id=1329835602549256959, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Schnell O, Standl E, Cos X, et al. Report from the 5th cardiovascular outcome trial (CVOT) summit[J]. Cardiovasc Diabetol, 2020, 19(1): 47., articleTitle=null, refAbstract=null), Reference(id=1329835602620560128, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Tyl B, Lopez Sendon J, Borer JS, et al. Comparison of outcome adjudication by investigators and by a central end point committee in heart failure trials: experience of the SHIFT heart failure study[J]. Circ Heart Fail, 2020, 13(7): e006720., articleTitle=null, refAbstract=null), Reference(id=1329835602696057601, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Patel T, Tesfaldet B, Chowdhury I, et al. Endpoints in diabetes cardiovascular outcome trials[J]. Lancet, 2018, 391(10138): 2412., articleTitle=null, refAbstract=null), Reference(id=1329835602750583554, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Lexicon Pharmaceuticals. Lexicon announces FDA approval of Inpefa (sotagliflozin) for treatment of heart failure[EB/OL]. [2023-06-01]. https://www.lexpharma.com/media-center/news/2023-05-26-lexicon-announces-fda-approval-of-inpefa-sotagliflozin-for-treatment-of-heart-failure., articleTitle=null, refAbstract=null)], funds=[Fund(id=1329835599235756775, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, awardId=2022LY004, language=CN, fundingSource=2022年度南通大学临床医学专项项目(2022LY004), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1329835597801304783, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, xref=1., ext=[AuthorCompanyExt(id=1329835597805499088, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, companyId=1329835597801304783, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Clinical Pharmacy, Haian People's Hospital, Haian 226600, Jiangsu Province, China), AuthorCompanyExt(id=1329835597818082001, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, companyId=1329835597801304783, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.海安市人民医院临床药学室,江苏 海安 226600)]), AuthorCompany(id=1329835597889385170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, xref=2., ext=[AuthorCompanyExt(id=1329835597901968083, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, companyId=1329835597889385170, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Cardiology, Haian People's Hospital, Haian 226600, Jiangsu Province, China), AuthorCompanyExt(id=1329835597914550996, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, companyId=1329835597889385170, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.海安市人民医院心血管内科,江苏 海安 226600)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.11.015, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.11.015, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2023.11.015, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2023.11.015, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1699545600000, fullTextJson=null, articleText=null, reference=null)
收藏切换
索格列净在心血管疾病中的研究进展
徐建华 1 , 王世亚 2, *
世界临床药物 | 综述评论 2023,44(11): 1215-1218
收起
收藏切换
世界临床药物 |综述评论 2023 , 44 (11) : 1215 -1218
索格列净在心血管疾病中的研究进展
全屏
[Author(id=1329835598036185814, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329835598124266200, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, authorId=1329835598036185814, language=EN, stringName=Jianhua XU, firstName=Jianhua, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Clinical Pharmacy, Haian People's Hospital, Haian 226600, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835598191375065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, authorId=1329835598036185814, language=CN, stringName=徐建华, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.海安市人民医院临床药学室,江苏 海安 226600, bio={"content":"

徐建华,副主任药师,临床药学负责人,研究方向:心血管临床药学。

"}, bioImg=null, bioContent=

徐建华,副主任药师,临床药学负责人,研究方向:心血管临床药学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835597801304783, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, xref=1., ext=[AuthorCompanyExt(id=1329835597805499088, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, companyId=1329835597801304783, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Clinical Pharmacy, Haian People's Hospital, Haian 226600, Jiangsu Province, China), AuthorCompanyExt(id=1329835597818082001, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, companyId=1329835597801304783, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.海安市人民医院临床药学室,江苏 海安 226600)])]), Author(id=1329835598321398491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329835598422061789, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, authorId=1329835598321398491, language=EN, stringName=Shiya WANG, firstName=Shiya, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Cardiology, Haian People's Hospital, Haian 226600, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835598489170654, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, authorId=1329835598321398491, language=CN, stringName=王世亚, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.海安市人民医院心血管内科,江苏 海安 226600, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835597889385170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, xref=2., ext=[AuthorCompanyExt(id=1329835597901968083, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, companyId=1329835597889385170, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Cardiology, Haian People's Hospital, Haian 226600, Jiangsu Province, China), AuthorCompanyExt(id=1329835597914550996, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835595481854668, companyId=1329835597889385170, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.海安市人民医院心血管内科,江苏 海安 226600)])])]
徐建华1, 王世亚2, *
作者信息
  • 1.海安市人民医院临床药学室,江苏 海安 226600
  • 2.海安市人民医院心血管内科,江苏 海安 226600
通讯作者:
王世亚,副主任医师,心内科副主任,研究方向:心血管内科各种常见病的诊治。
作者简介:

徐建华,副主任药师,临床药学负责人,研究方向:心血管临床药学。

Research progress of sotagliflozin in cardiovascular disease
Jianhua XU1, Shiya WANG2, *
Affiliations
  • 1.Department of Clinical Pharmacy, Haian People's Hospital, Haian 226600, Jiangsu Province, China
  • 2.Department of Cardiology, Haian People's Hospital, Haian 226600, Jiangsu Province, China
出版时间: 2023-11-10 doi: 10.13683/j.wph.2023.11.015
文章导航
收藏切换

索格列净(sotagliflozin)是一种对钠-葡萄糖协同转运蛋白(sodium-dependent glucose transporters,SGLT)1、2有双重抑制作用的药物,对SGLT1的抑制可抑制消化道葡萄糖和半乳糖的吸收,对SLGT2抑制则是减少肾小管对葡萄糖的重吸收,已被证明可有效治疗2型糖尿病(diabetes mellitus)。近年来,其在心血管疾病方面显示出巨大潜力。索格列净能降低2型糖尿病伴心血管危险因素患者的心血管不良事件。该文通过对近年来国内外索格列净对糖尿病合并心血管疾病应用的研究进行归纳总结,以期为索格列净在心血管方面的进一步应用提供指导。

索格列净  /  糖尿病  /  心血管  /  心力衰竭

Sotagliflozin is a drug with dual inhibitory effects on sodium-dependent glucose transporters (SGLT) 1 and 2. Inhibition of SGLT1 can inhibit glucose and galactose absorption in the digestive tract, and inhibition of SLGT2 can reduce glucose reabsorption in the renal tubules. Sotagliflozin has been shown to be effective in the treatment of type 2 diabetes mellitus. In recent years, it has shown great potential in cardiovascular diseases. Soglitazone can reduce adverse cardiovascular events in type 2 diabetes patients with cardiovascular risk factors. This article summarized the research on the application of sotagliflozin in diabetes mellitus complicated with cardiovascular diseases at home and abroad in recent years, in order to provide guidance for the further application of sotagliflozin in cardiovascular diseases.

sotagliflozin  /  diabetes melltius  /  cardiovascular  /  heart failure
徐建华, 王世亚. 索格列净在心血管疾病中的研究进展. 世界临床药物, 2023 , 44 (11) : 1215 -1218 . DOI: 10.13683/j.wph.2023.11.015
Jianhua XU, Shiya WANG. Research progress of sotagliflozin in cardiovascular disease[J]. World Clinical Drug, 2023 , 44 (11) : 1215 -1218 . DOI: 10.13683/j.wph.2023.11.015
  • 2022年度南通大学临床医学专项项目(2022LY004)
参考文献 引证文献
排序方式:
[1]
李钰. 新型降糖药对2型糖尿病患者卒中和心血管结局影响的meta分析[D]. 石家庄: 河北医科大学, 2022.
[2]
Scirica BM, Bhatt DL, Braunwald E, et al. Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial[J]. J Am Med Assoc Cardiol, 2016, 1(9): 989-998.
[3]
潘丽. 糖尿病与心血管疾病相互联系分析[J]. 糖尿病新世界, 2015, (7): 134.
[4]
朱思梅, 杨汉跃, 王建涛. SGLT1/SGLT2双重抑制剂索格列净用于1型糖尿病的研究进展[J]. 中国新药与临床杂志, 2018, 37(10): 537-540.
[5]
杨中兴, 贺岩, 杨龙, 等. SGLT1/2双靶点抑制剂的研究进展[J]. 中南药学, 2021, 19(9): 1776-1785.
[6]
Powell DR, Zambrowicz B, Morrow L, et al. Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption[J]. J Clin Endocrinol Metab, 2020, 105(4): e1235-e1249.
[7]
Seidelmann SB, Feofanova E, Yu B, et al. Genetic variants in SGLT1, glucose tolerance, and cardiometabolic risk[J]. J Am Coll Cardiol, 2018, 72(15): 1763-1773.
[8]
Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure[J]. N Engl J Med, 2021, 384(2): 117-128.
[9]
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4): 347-357.
[10]
Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus[J]. Circulation, 2019, 139(22): 2528-2536.
[11]
Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med, 2020, 383(15): 1436-1446.
[12]
Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes[J]. N Engl J Med, 2020, 383(15): 1425-1435.
[13]
Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)[J]. Eur J Heart Fail, 2020, 22(4): 713-722.
[14]
Verma S, Mazer CD, Bhatt DL, et al. Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG outcome trial[J]. Diabetes Care, 2019, 42(3): e42-e44.
[15]
Verma S, Mazer CD, Yan AT, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial[J]. Circulation, 2019, 140(21): 1693-1702.
[16]
Opingari E, Verma S, Connelly KA, et al. The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of empagliflozin on cardiac structure, function, and circulating biomarkers in patients with type 2 diabetes CardioLink-6 trial[J]. Nephrol Dial Transplant, 2020, 35(5): 895-897.
[17]
Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease[J]. N Engl J Med, 2021, 384(2): 129-139.
[18]
Bagiella E, Bhatt DL, Gaudino M. The consequences of the COVID-19 pandemic on non-COVID-19 clinical trials[J]. J Am Coll Cardiol, 2020, 76(3): 342-345.
[19]
Gaba P, Bhatt DL. The COVID-19 pandemic: a catalyst to improve clinical trials[J]. Nat Rev Cardiol, 2020, 17(11): 673-675.
[20]
Gaudino M, Arvind V, Hameed I, et al. Effects of the COVID pandemic on active non-COVID clinical trials[J]. J Am Coll Cardiol, 2020, 76(13): 1605-1606.
[21]
Selvaraj S, Greene SJ, Khatana SAM, et al. The landscape of cardiovascular clinical trials in the United States initiated before and during COVID-19[J]. J Am Heart Assoc, 2020, 9(18): e018274.
[22]
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22): 2117-2128.
[23]
Neal B, PerkovicV, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med, 2017, 377(21): 2099.
[24]
Schnell O, Standl E, Cos X, et al. Report from the 5th cardiovascular outcome trial (CVOT) summit[J]. Cardiovasc Diabetol, 2020, 19(1): 47.
[25]
Tyl B, Lopez Sendon J, Borer JS, et al. Comparison of outcome adjudication by investigators and by a central end point committee in heart failure trials: experience of the SHIFT heart failure study[J]. Circ Heart Fail, 2020, 13(7): e006720.
[26]
Patel T, Tesfaldet B, Chowdhury I, et al. Endpoints in diabetes cardiovascular outcome trials[J]. Lancet, 2018, 391(10138): 2412.
[27]
Lexicon Pharmaceuticals. Lexicon announces FDA approval of Inpefa (sotagliflozin) for treatment of heart failure[EB/OL]. [2023-06-01]. https://www.lexpharma.com/media-center/news/2023-05-26-lexicon-announces-fda-approval-of-inpefa-sotagliflozin-for-treatment-of-heart-failure.
2023年第44卷第11期
13
1
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2023.11.015
  • 接收时间:2023-06-19
  • 首发时间:2026-11-18
  • 出版时间:2023-11-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2023-06-19
基金
2022年度南通大学临床医学专项项目(2022LY004)
作者信息
    1.海安市人民医院临床药学室,江苏 海安 226600
    2.海安市人民医院心血管内科,江苏 海安 226600

通讯作者:

王世亚,副主任医师,心内科副主任,研究方向:心血管内科各种常见病的诊治。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.11.015
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏